An interventional study of Lymphoblock and Placebo in Aorta Abdominalis; Aneurysm and Aorta Thoracic; Aneurysm, sponsored by Petrovsky National Research Centre of Surgery. Recruiting at 1 site in Russian Federation. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-15.
Sponsored by Petrovsky National Research Centre of Surgery · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Randomized, double-blind, placebo-controlled study will determine the clinical efficacy and safety of Lymphoblock in the prevention of postoperative retroperitoneal chylo-/lymphorrhoea in patients with open surgical treatment of the thoracoabdominal aorta. It is planned to recruit 138 clinical observations. Efficacy will be evaluated based on clinical and laboratory data.
The study design will include patients with open surgical repair of the thoracoabdominal aorta who underwent thoracophrenolumbotomy with retroperitoneal exposure of the aorta. It is assumed the lymphoblock to reduce the incidence of postoperative lympho-/chylorrhea. Patients will be divided based on randomization into groups that will receive a lymphoblock or a placebo. It is planned to recruit 138 patients, 69 patients in each group. The drug will be used right before wound closure. The solution will be applied to the surface of the wound with further exposure and draining. Blood test and drainage discharge parameters (from the left pleural cavity and retroperitoneum) will be examined in postoperative period. The thoracic and abdominal CT and ultrasound will be performed to exclude presence of effusion and/or lymphocele.
467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.
This study's planned enrollment of 138 is above the median of 66 across 228 interventional studies indexed under Aortic Aneurysm, Abdominal.
Browse Aortic Aneurysm, Abdominal studies →Petrovsky National Research Centre of Surgery is the lead sponsor of 18 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients from this group received Lymphoblock.
Device: Lymphoblock
Patients from this group received placebo.
Device: Placebo
1 time per surgery with the exposition for 20 minutes.
1 time per surgery with the exposition for 20 minutes.
Number of Participants with Chylous Effusion (Сhilo-/lymphorrhea)
This outcome will be determined by assessing the milky of the drainage discharge, and comparing the content of triglycerides, glucose, cholesterol and lactate dehydrogenase (LDH) in the drainage discharge with those in the blood plasma
Time frame: within 10 days of starting a regular diet after surgery
Number of Participants with Lymphocele
retroperitoneal liquid formation ≥5 cm in diameter according to ultrasound after drainage removal
Time frame: 10 days after the surgery in patient who starting a regular diet after drainage removal
The amount of drainage discharge 1
volume of drainage discharge obtained in the first 24 hours after surgery, measured in milliliters (ml)
Time frame: 24 hours after the surgery
The amount of drainage discharge 2
volume of drainage discharge obtained in the first 48 hours after surgery, measured in milliliters (ml)
Time frame: 48 hours after the surgery
The amount of drainage discharge 3
volume of drainage discharge obtained in the first 72 hours after surgery, (ml)
Time frame: 72 hours after the surgery
Concentration of triglycerides in the drainage discharge
count of triglycerides in the drainage discharge, received from drainage tube, (mg/dL)
Time frame: 72 hours after the surgery
Concentration of triglycerides in blood plasma
count of triglycerides in the blood plasma, (mg/dL)
Time frame: 72 hours after the surgery
Concentration of cholesterol in the drainage discharge
count of cholesterol in the drainage discharge, received from drainage tube, (mg/dL)
Time frame: 72 hours after the surgery
Concentration of cholesterol in the blood plasma
count of cholesterol in the blood plasma, (mg/dL)
Time frame: 72 hours after the surgery
Concentration of protein in the drainage discharge
count of total protein in the drainage discharge, received from drainage tube, (g/dL)
Time frame: 72 hours after the surgery
Concentration of protein in the blood plasma
count of total protein in the blood plasma, (g/dL)
Time frame: 72 hours after the surgery
Concentration of albumin in the drainage discharge
count of albumin in the drainage discharge, received from drainage tube, (g/dL)
Time frame: 72 hours after the surgery
Concentration of albumin in the blood plasma
count of albumin in the blood plasma, (g/dL)
Time frame: 72 hours after the surgery
Concentration of lactate dehydrogenase in the drainage discharge
count of albumin in the drainage discharge, received from drainage tube (IU/L)
Time frame: 72 hours after the surgery
Concentration of lactate dehydrogenase in the blood plasma
count of lactate dehydrogenase in the blood plasma (IU/L)
Time frame: 72 hours after the surgery
Concentration of glucose in the drainage discharge
Content of glucose in the drainage discharge, received from drainage tube, (mg/dL)
Time frame: 72 hours after the surgery
Concentration of glucose in the blood plasma
Content of glucose in the blood plasma (mg/dL)
Time frame: 72 hours after the surgery
Number of Participants with Pleural effusion within 10 days
left pleural fluid accumulations (≥500 ml) after drainage removal drainage removal
Time frame: 10 days after the surgery in patient who starting a regular diet after drainage removal
Number of Participants with Lymphocele 3 months after the surgery
liquid formation ≥5 cm in diameter according to ultrasound after drainage removal
Time frame: 3 months after the surgery
Number of Participants with Pleural effusion 3 months after the surgery
left pleural fluid accumulations (≥500 ml) after drainage removal
Time frame: 3 months after the surgery
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Feb 2026, 36 months after the start.
Of 51 non-industry interventional studies with no phase under Aortic Aneurysm, Abdominal, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 61. This study's planned 36 months is below that.
Counting every sponsor, half of 94 studies reached it within 43 months; a quarter within 23 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Petrovsky National Research Centre of Surgery